Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Equities research analysts at William Blair lifted their Q1 2024 EPS estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Thursday, March 21st. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of ($0.39) […]